• Drug Response Metrics in Cancer In Vitro

  2026-09-03

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different relationships between growth inhibition and cell death. The framework supports more informative in vitro drug-response studies by combining dose- and time-resolved measurements rather than treating a single viability endpoint as a direct measure of cytotoxicity.

• 40-Hz Flicker, MHC-II+ Microglia, and Retinal Aβ

  2026-09-03

  A 2026 mouse study links 40-Hz light flicker to increased MHC-II expression, microglial activation, and amyloid-β clearance in the retina. Pharmacological suppression of microglial activity eliminated both clearance and functional benefits, supporting a microglia-dependent mechanism while leaving important questions about MHC-II causality and human translation.

• AG-120 for Mutant IDH1 Assay Design

  2026-09-02

  A scenario-based guide to using AG-120 (Ivosidenib), mutant IDH1 inhibitor (SKU B7805) in viability, proliferation, and differentiation workflows. It connects 2-hydroxyglutarate reduction with assay controls, dosing design, storage, and interpretation in AML mutant IDH1 models.

• Dextrose for Hypoxia Immunometabolism Workflows

  2026-09-02

  Build controlled glucose gradients for hypoxia, tumor–immune co-culture, glycolysis, and cellular energy production studies with a reproducible D-glucose substrate. This workflow combines paired nutrient conditions, oxygen control, time-course sampling, and troubleshooting guidance to improve interpretation across glucose metabolism research and diabetes research.

• Methyl-β-cyclodextrin Workflow Guide

  2026-09-01

  Methyl-β-cyclodextrin (SKU C6939) provides a controllable reagent strategy for membrane cholesterol extraction and related studies of lipid organization, membrane fluidity, and signaling. It is for controlled scientific research only; working concentration, exposure time, and biological effects must be established in the investigator’s own assay rather than inferred from a universal protocol.

• GSH and GSSG Assay Kit for Tumor Redox Research

  2026-09-01

  Translate hypoxia and immunometabolism questions into quantitative redox endpoints with matched total glutathione, GSH, and GSSG measurements. This practical workflow highlights sample handling, selective GSSG analysis, matrix control, and troubleshooting across tumor, immune, tissue, plasma, and cell models.

• GSK2606414: From PERK Mechanism to Translation

  2026-08-31

  A translational perspective on GSK2606414 as a selective PERK inhibitor, connecting ER stress biology with PERK-dependent pyroptosis, assay design, cancer research, and disease-model strategy.

• ATM Inhibition and Fenofibrate in HGSOC

  2026-08-31

  The reference study identifies a metabolism-linked vulnerability in high-grade serous ovarian cancer (HGSOC): ATM suppression enhances the activity of fenofibrate, a PPARα agonist, in ATM-low cellular contexts. Its principal contribution is to connect DNA damage response inhibition with metabolic intervention and senescence, suggesting a combination strategy that may extend beyond tumors with homologous recombination deficiency.

• Azathramycin A: From Ribosome Binding to TB Translation

  2026-08-30

  Azathramycin A offers translational researchers a mechanistic probe for studying macrolide-driven disruption of Mycobacterium tuberculosis protein synthesis. This thought-leadership guide connects ribosome engagement, degradation-state control, matrix-aware assay design, PK/PD reasoning, and antibiotic resistance research while clearly separating research opportunity from clinical evidence.

• MG-262 Proteasome Inhibition: Practical Workflows

  2026-08-29

  MG-262 enables time-controlled proteasome inhibition in intact cells, making it useful for ubiquitin-proteasome studies, apoptosis research, and cell cycle arrest studies. This guide connects reversible inhibitor handling with cytokine-responsive pulmonary epithelial assays and dose-sensitive osteoclast differentiation inhibition.

• DPPH Antioxidant Screening Workflow

  2026-08-28

  Build a reproducible DPPH workflow for rapid in vitro antioxidant screening, natural product comparison, and compound prioritization. The protocol combines plate-based colorimetry with orthogonal assays and UPLC-MS/MS so radical-scavenging results become more useful for high-throughput antioxidant screening and lead discovery.

• ERAD Hijacking for TM Protein Degradation

  2026-08-28

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule strategy that redirects transmembrane proteins to the ER-associated degradation pathway. By using desonide to recruit the ER E3 ligase SYVN1, the study achieves highly effective PD-L1 degradation and demonstrates tumor-suppression activity, while also extending the concept to mutant HTT.

• CLEC5A and ISG20 in Atherosclerosis: Causal Evidence

  2026-08-27

  Zhang et al. integrated GEO transcriptomic data, eQTL evidence, Mendelian randomization, and experimental validation to identify CLEC5A and ISG20 as genes associated with atherosclerosis risk. The study gives particular mechanistic attention to ISG20, linking its increased expression with macrophage lipid accumulation and inflammatory features in cellular and ApoE–/– mouse models.

• Vasopressin Analogues: Findings from a 2022 Review

  2026-08-26

  Glavaš and colleagues present an integrative review of vasopressin biology, receptor pharmacology, and the design of peptide and non-peptide analogues with distinct therapeutic profiles. The article shows how lypressin, desmopressin, terlipressin, and related compounds address different limitations of native vasopressin while also identifying important translational gaps in receptor selectivity, metabolic stability, and emerging antiviral applications.

• Azathramycin A: From Degradation to TB Assays

  2026-08-26

  Azathramycin A is a macrolide antibiotic and ribosome-binding research compound with unusual value as both a tuberculosis assay probe and azithromycin degradation marker. This guide develops a stability-aware workflow and explains how PK/PD evidence from gamithromycin can inform, but not replace, direct Azathramycin A experiments.

8074 records 1/539 page Next 12345 下5页 Last page